Table 3. Comparative Cost-Effectiveness of Statin Use for Primary Prevention of Coronary Heart Disease (2016-2025), Relative to Status Quo.
ATP III | ACC-AHA | Age/Sex-Based | |
---|---|---|---|
Total Additional Persons Acted On* | 8.76 m† | 21.0 m | 49.9 m |
Total Cost | -$10.7 b | -14.6 b | -$26.0 b |
Treatment costs ‡ | $8.29 b | $21.6 b | $35.0 b |
Screening costs§ | $2.65 b | $6.36 b | $4.65 b |
Savings from events averted | -$19.0 b | -$36.1 b | -$61.1 b |
Incident CHD Events Averted | 341,000 | 578,000 | 999,000 |
QALYs Saved | 253,000 | 436,000 | 705,000 |
Lives Saved | 42,300 | 86,000 | 135,000 |
Total Cost per QALY (ICER) | Cost-saving | Cost-saving | Cost-saving |
NNT per QALY | 35 | 49 | 71 |
NNT per Life Saved | 205 | 245 | 370 |
Total persons are relative to the status quo scenario.
7.6 million started on statins de novo; 1.2 with prior dose intensified.
All costs of treatment (including medication costs).
The cost of adverse outcomes; lipid and liver function tests; and physician visits associated with statin use.